We are live on ! Find out more
PSTV

Plus Therapeutics
PSTV

Delisted

PSTV was delisted on the 31st of July, 2026.

Back to rankings

5 hedge funds and large institutions have $952K invested in Plus Therapeutics in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0% → 0% (-0%)

17% less funds holding

Funds holding: 6 → 5 (-1)

79% less capital invested

Capital invested by funds: $4.51M → $952K (-$3.56M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
5
Holders Change
-1
Holders Change %
-16.67%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
1
Calls
$17K
Puts
–
Net Calls
+$17K
Net Calls Change
-$11K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$99.6K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.79M
2
MCM
Marathon Capital Management
Maryland
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
PCM
1
Perkins Capital Management
Minnesota
$335K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$256K +$99.6K +1 +33%
BlackRock
3
BlackRock
New York
$116K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$62K – – –
Renaissance Technologies
5
Renaissance Technologies
New York
$43K – – –
Creative Planning
6
Creative Planning
Kansas
$29K – – –
Northern Trust
7
Northern Trust
Illinois
$20K – – –
UBS Group
8
UBS Group
Switzerland
$18K – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$11K – – –
VF
10
Virtu Financial
New York
$10K – – –
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$9K – – –
IP
12
Intellectus Partners
California
$7K – – –
UB
13
UMB Bank
Missouri
$7K – – –
HighTower Advisors
14
HighTower Advisors
Illinois
$6K – – –
TSS
15
Two Sigma Securities
New York
$6K – – –
California Public Employees Retirement System
16
California Public Employees Retirement System
California
$5K – – –
FPF
17
FNY Partners Fund
New York
$5K – – –
PMFA
18
Plante Moran Financial Advisors
Michigan
$2K – – –
Simplex Trading
19
Simplex Trading
Illinois
$2K – – –
Barclays
20
Barclays
United Kingdom
$1K – – –
Morgan Stanley
21
Morgan Stanley
New York
$1K – – –
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
$1K – – –
FDCDDQ
23
Federation des caisses Desjardins du Quebec
Quebec, Canada
$49 – – –
SM
24
Sabby Management
Florida
– -$1.79M -9 Closed
MCM
25
Marathon Capital Management
Maryland
– -$12K – –

PSTV Hedge Fund Activity: Q3 2017 in Review

5 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2017, worth a combined $952K — down 79% from $4.51M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of PSTV and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.

The largest buyer was Vanguard Group, adding an estimated $99.6K. The largest seller was Sabby Management, exiting entirely with an estimated $1.79M sold.

  • 5 institutional investors held Plus Therapeutics (PSTV) as of Q3 2017, down from 6 in Q2 2017.
  • Funds reported $952K of Plus Therapeutics stock for Q3 2017, down 79% quarter-over-quarter.
  • 0 funds opened new Plus Therapeutics positions in Q3 2017 and 1 closed out, a net change of -1 holder.
  • The largest Plus Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $99.6K added.
  • The largest Plus Therapeutics seller in Q3 2017 was Sabby Management, an estimated $1.79M sold.

Based on aggregated 13F filings for Q3 2017.